Impact of randomized clinical trials on therapy of primary breast cancer: the NSABP overview.

[1]  B. Hoogstraten,et al.  Combination chemotherapy (CMFVP) versus L‐phenylalanine mustard (L‐PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group study , 1982, Cancer.

[2]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[3]  C. Redmond,et al.  The contribution of recent nsabp clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findings , 1980, Cancer.

[4]  C. Redmond,et al.  L‐phenylalanine mustard (L‐PAM) in the management of primary breast cancer: An update of earlier findings and a comparison with those utilizing L‐PAM plus 5‐fluorouracil (5‐FU) , 1977, Cancer.

[5]  P. Band,et al.  Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. , 1976, Cancer treatment reports.

[6]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.

[7]  H. Ward.  Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels , 1973, British medical journal.

[8]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[9]  R K Ausman,et al.  Surgical Adjuvant Chemotherapy in Cancer of the Breast: Results of a Decade of Cooperative Investigation , 1968, Annals of surgery.

[10]  W. Halsted.  I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. , 1907, Annals of surgery.

[11]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.